OptiNose (NASDAQ:OPTN) Announces Quarterly Earnings Results

Share on StockTwits

OptiNose (NASDAQ:OPTN) released its quarterly earnings results on Monday. The company reported ($0.66) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.75) by $0.09, Bloomberg Earnings reports. The firm had revenue of $6.68 million for the quarter, compared to analysts’ expectations of $7.74 million. OptiNose had a negative net margin of 983.22% and a negative return on equity of 81.04%.

OptiNose stock opened at $6.26 on Wednesday. The firm has a 50-day moving average of $6.30. OptiNose has a twelve month low of $4.44 and a twelve month high of $19.92. The company has a market cap of $258.31 million, a PE ratio of -2.34 and a beta of 0.90. The company has a debt-to-equity ratio of 0.79, a quick ratio of 6.74 and a current ratio of 6.95.

Several research firms have weighed in on OPTN. ValuEngine raised shares of OptiNose from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Piper Jaffray Companies set a $29.00 price target on shares of OptiNose and gave the company a “buy” rating in a report on Tuesday, April 23rd. BMO Capital Markets lowered their price target on shares of OptiNose from $26.00 to $24.00 and set an “outperform” rating on the stock in a report on Tuesday. Zacks Investment Research cut shares of OptiNose from a “buy” rating to a “hold” rating in a report on Thursday, July 11th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $27.00 price target on shares of OptiNose in a report on Thursday, May 9th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $22.50.

Several large investors have recently made changes to their positions in the business. Northern Trust Corp grew its position in shares of OptiNose by 0.8% during the 2nd quarter. Northern Trust Corp now owns 227,704 shares of the company’s stock worth $1,611,000 after purchasing an additional 1,797 shares in the last quarter. BNP Paribas Arbitrage SA grew its position in shares of OptiNose by 1,569.2% during the 1st quarter. BNP Paribas Arbitrage SA now owns 4,006 shares of the company’s stock worth $41,000 after purchasing an additional 3,766 shares in the last quarter. Swiss National Bank grew its position in shares of OptiNose by 36.4% during the 2nd quarter. Swiss National Bank now owns 30,700 shares of the company’s stock worth $217,000 after purchasing an additional 8,200 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of OptiNose by 6.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 155,873 shares of the company’s stock worth $1,104,000 after purchasing an additional 9,516 shares in the last quarter. Finally, Stifel Financial Corp acquired a new position in shares of OptiNose during the 4th quarter worth approximately $63,000. Hedge funds and other institutional investors own 63.78% of the company’s stock.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Further Reading: How is the LIBOR rate calculated?

Earnings History for OptiNose (NASDAQ:OPTN)

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

OptiNose  Announces Quarterly  Earnings Results
OptiNose Announces Quarterly Earnings Results
II-VI  Updates Q1 2020 Earnings Guidance
II-VI Updates Q1 2020 Earnings Guidance
FlexShopper  Posts  Earnings Results, Beats Estimates By $0.05 EPS
FlexShopper Posts Earnings Results, Beats Estimates By $0.05 EPS
Arcadia Biosciences’  Buy Rating Reiterated at HC Wainwright
Arcadia Biosciences’ Buy Rating Reiterated at HC Wainwright
LRAD  Issues  Earnings Results, Misses Estimates By $0.01 EPS
LRAD Issues Earnings Results, Misses Estimates By $0.01 EPS
Brinker International  Releases FY 2020 Earnings Guidance
Brinker International Releases FY 2020 Earnings Guidance


© 2006-2019 Ticker Report